Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases

Expert Opinion on Drug Delivery

Volumn 13, Issue 8, 2016, Pages 1121-1131

  Cacciatore, Ivana ^a   Ciulla, Michele ^a   Fornasari, Erika ^a   Marinelli, Lisa ^a   Di Stefano, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alzheimer s disease; Drug delivery; Parkinson s disease; solid lipid nanoparticles

Indexed keywords

ANTIOXIDANT; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CARDIOLIPIN; CURCUMIN; DONEPEZIL; EPIGALLOCATECHIN GALLATE; FERULIC ACID; GALANTAMINE; GLYCEROL BEHENATE; IDEBENONE; LEVODOPA; LUTEOLIN; MACROGOL; PHOSPHATIDIC ACID; PIPERINE; QUERCETIN; RILUZOLE; RIVASTIGMINE; ROPINIROLE; ROSMARINIC ACID; ROTIGOTINE; SOLID LIPID NANOPARTICLE; THIOCTIC ACID; TRISTEARIN; LIPID; NANOPARTICLE;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENZYME DEGRADATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NANOPHARMACEUTICS; NONHUMAN; PARKINSON DISEASE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLISM; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES;

BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES;

EID: 84965000136     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1178237     Document Type: Review

References (71)

1. M.R.Gasco Method for producing solid lipid microspheres having a narrow size distribution. US 5250236. 1993.
2. M.Radtke, R.H.Müller Comparison of structural properties of solid lipid nanoparticles (SLN) versus other lipid particles. ProcIntSymp Control RelBioact Mater. 2000;27:309–310.
3. S.Gohla, A.Dingler. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie. 2001;56:61–63.
4. B.Kante, P.Couvreur, G.Dubois-Krack, et al. Toxicity of polyalkylcyanoacrylate nanoparticles I: free nanoparticles. J PharmaSci. 1982;71:786–790.
5. R.Nair, K.S.Arun Kumar, K.Vishnu Priya, et al. Recent advances in solid lipid nanoparticle based drug delivery systems. J Biomed Sci and Res. 2011;3:368–384.
6. S.Mukherjee, S.Ray, R.S.Thakur. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71:349–358.
7. R.H.Müller, M.Radtke, S.A.Wissing. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155.
8. W.Menhert, K.Mäder. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
9. M.Patel, E.B.Souto, K.K.Singh. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10:889–905.
10. S.A.Wissing, O.Kayser, R.H.Müller. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272.
11. M.Uner. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375–386.
12. P.Sozio, J.Fiorito, V.Di Giacomo, et al. Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells. Eur J Med Chem. 2014;90:1–9.
13. S.Laserra, A.Basit, P.Sozio, et al. Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization. Int J Pharm. 2015;485:183–191.
14. L.Gastaldi, L.Battaglia, E.Peira, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87:433–444.
15. M.O.Oyewumia, R.A.Yokela, M.Jaya, et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Contr Release. 2004;95:613–626.
16. S.M.Moghimi, C.J.H.Porter, I.S.Muir, et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. BiochemBiophys Res Commun. 1991;177:861–866.
17. P.Aggarwal, J.B.Hall, C.B.McLeland, et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61:428–437.
18. S.M.Moghimi, A.C.Hunter, J.C.Murray. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.
19. F.Alexis, E.Pridgen, L.K.Molnar, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
20. O.C.Farokhzad, R.Langer. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Delivery Rev. 2006;58:1456–1459.
21. W.M.Pardridge. Why is the global CNS pharmaceutical market so underpenetrated? Drug Discov Today. 2002;7:5–7.
22. R.Cecchelli, V.Berezowski, S.Lundquist, et al. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6:650–661.
23. P.Ballabh, A.Braun, M.Nedergaard. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13.
24. D.E.Clark. In silico prediction of blood–brain barrier permeation. Drug Discov Today. 2003;8:927–933.
25. P.Sozio, L.S.Cerasa, S.Laserra, et al. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer’s disease. Eur J Pharm Sci. 2013;49:187–198.
26. S.Nelluri, J.V.Felix, K.S.Sathesh. Formulation and evaluation of galantamine nanoparticles for neurological disorders. Int J Pharm Chem Biol Sci. 2015;5:63–70.
27. M.Yusuf, M.Khan, R.A.Khan, et al. Preparation, characterization, in vivo and biochemical evaluation of brain targeted piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 2013;21:300–311.
28. S.Dhawan, R.Kapil, B.Singh. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63:342–351.
29. A.Orlando, F.Re, S.Sesana, et al. Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. Int J Nanomedicine. 2013;8:1335–1347.
30. P.Picone, M.L.Bondi, G.Montana, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radical Res. 2009;43:1133–1145.
31. A.Smith, B.Giunta, P.C.Bickford, et al. Nanolipidic particles improve the bioavailability and γ-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm. 2010;389:207–212.
32. V.Kakkar, I.P.Kaur, Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol. 2011;49:2906–2913.•• The study highlights the potential use of CU-SLN for the treatment of AD. The paper gives a direct evidence of effective brain delivery SLN and for the first time establishes the curative-therapeutic role of curcumin.
33. J.Wang, R.Zhu, D.Sun, et al. Intracellular uptake of curcumin-loaded solid lipid nanoparticles exhibit anti-inflammatory activities superior to those of curcumin through the NF-κB signaling pathway. J Biomed Nanotechnol. 2015;11(3):403–415.
34. R.Sandhir, A.Yadav, A.Mehrotra, et al. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuromolecolar Med. 2014;16:106–118.
35. J.Wang, H.Wang, R.Zhu, et al. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1β transgenic mice subjected to the lipopolysaccharide-induced sepsis. Biomaterials. 2015;53:475–483.
36. P.K.Gaur, S.Mishra, A.Verma, et al. Ceramide-palmitic acid complex based curcumin solid lipid nanoparticles for transdermal delivery: pharmacokinetic and pharmacodynamic study. J Exp Nanosci. 2015. doi:10.1080/17458080.2015.1025301.
37. S.A.Frautschy, G.M.Cole Bioavailable curcuminoid formulations for treating Alzheimer’s disease and other age-related disorders. WO 2007103435 A2 20070913. 2007.
38. S.Zhan, D.Hou, Q.Ping, et al. Preparation and entrapment efficiency determination of solid lipid nanoparticles loaded levodopa. Zhongguo Yiyuan Yaoxue Zazhi. 2010;30:1171–1175.
39. E.Esposito, M.Fantin, M.Marti, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 2008;25(7):1521–1530.
40. L.Wu, W.Watanabe Sustained-release formulation of rotigotine. WO2014205031 A120141224. 2014.
41. M.J.Tsai, Y.B.Huang, P.C.Wu, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 2011;100(2):547–557.
42. C.V.Pardeshi, P.V.Rajput, V.S.Belgamwar, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv. 2013;20(1):47–56.•• The paper deals with intranasal delivery of ropinirole hydrochloride loaded in SLN to avoid the hepatic first-pass metabolism and to improve therapeutic efficacy in the treatment of Parkinson’s disease.
43. E.B.Souto, R.H.Mueller, S.Gohla. A novel approach based on lipid nanoparticles (SLN) for topical delivery of α-lipoic acid. J Microencapsul. 2005;22:581–592.
44. L.Montenegro, A.Campisi, M.G.Sarpietro, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011;37:737–746.
45. Z.Ge, B.Li Idebenone-loaded nano lipid carrier transdermal preparation and manufacture method thereof. CN 102091038 A 20110615. 2011.
46. H.Dang, M.Hasan, W.Meng, et al. Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies. J Nanopart Res. 2014;16:2347–2357.
47. M.L.Bondì, E.F.Craparo, G.Giammona, et al. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine. 2010;5:25–32.
48. R.Bhatt, D.Singh, A.Prakash, et al. Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Drug Deliv. 2015;22:931–939.
49. M.Masserini. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:18. Article ID 238428.
50. C.Burlà, G.Rego, R.Nunes. Alzheimer, dementia and the living will: a proposal. Med Health Care Philos. 2014;17:389–395.
51. A.J.Saykin, H.A.Wishart, L.A.Rabin, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127:1574–1583.
52. K.G.Yiannopoulou, S.G.Papageorgiou. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Dis. 2013;6:19–33.
53. B.Reisberg, R.Doody, A.Stöffler, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341.
54. J.L.Cummings Optimizing phase II of drug development for disease-modifying compounds. Alzheimer’s and Dementia. 2008;4:S15–S20.
55. D.Galimberti, E.Scarpini. Disease-modifying treatments for Alzheimer’s disease. Therap Adv Neurol Dis. 2011;4:203–216.
56. I.Cacciatore, L.Baldassarre, E.Fornasari, et al. (R)-α-Lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as a multifunctional agent with potential neuroprotective activities. Chem Med Chem. 2012;7:2021–2029.
57. P.Sozio, E.D’Aurizio, A.Iannitelli, et al. Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch Pharm. 2010;343:133–142.
58. J.Hardy, D.J.Selkoe. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.
59. 42 peptide in all its aggregation forms.
60. A.H.Rajput. Frequency and cause of Parkinson’s disease. Can J Neurol Sci. 1992;19:103–107.
61. A.Sami, J.G.Nutt, B.R.Ransom. Parkinson’s disease. Lancet. 2004;363:1783–1793.
62. L.M.De Lau, M.M.Breteler. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–535.
63. P.Sozio, A.Iannitelli, L.S.Cerasa, et al. New L-dopa codrugs as potential antiparkinson agents. Arch Pharm. 2008;341:412–417.
64. A.Minelli, C.Conte, I.Cacciatore, et al. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson’s animal model. Amino Acids. 2012;43:1359–1367.
65. A.Minelli, C.Conte, E.Prudenzi, et al. N-Acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity. Free Rad Biol Med. 2010;49:31–39.
66. J.Jankovic, M.Stacy. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21(8):677–692.
67. G.M.Cingolani, A.Di Stefano, B.Mosciatti, et al. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. Bioorg Med Chem Lett. 2000;10:1385–1388.
68. P.Sozio, E.D’Aurizio, A.Iannitelli, et al. Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Archiv Pharm. 2010;343:133–142.
69. I.Cacciatore, A.M.Caccuri, A.Di Stefano, et al. Synthesis and activity of novel glutathione analogues containing an urethane backbone linkage. Farmaco. 2003;58:787–793.
70. I.Cacciatore, C.Cornacchia, E.Fornasari, et al. A glutathione derivative with chelating and in vitro neuroprotective activities: synthesis, physicochemical properties, and biological evaluation. Chem Med Chem. 2013;8:1818–1829.
71. A.Patruno, E.Fornasari, A.Di Stefano, et al. Synthesis of a novel cyclic prodrug of S -allyl-glutathione able to attenuate LPS-induced ROS production through the inhibition of MAPK pathways in U937 cells. Mol Pharm. 2015;12:66–74.